Skip to main content

Table 2 Overall mean (SD) AKQoL, DLQI, EQ-5D-5 L, and EQ-VAS values and in subgroups of patients

From: Health related quality of life in patients with actinic keratosis – an observational study of patients treated in dermatology specialist care in Denmark

  

AK-QoL

DLQI

EQ-5D-5 L

EQ-VAS

  

n

Mean

SD

p-value

n

Mean

SD

p-value

n

Mean

SD

p-value

n

Mean

SD

p-value

Total population

 

286a

6.7

4.8

 

290b

1.99

2.71

 

276c

0.884

0.140

 

284

79.3

18.9

 

Sex

Men

137

5.3

3.7

<0.001

138

1.73

2.46

0.121

132

0.901

0.127

0.060

136

81.3

17.9

0.086

 

Women

149

7.9

5.3

 

152

2.23

2.91

 

144

0.868

0.150

 

148

77.6

19.7

 

Age groupsd

<60

38

8.1

5.5

0.004

39

2.31

2.40

0.657

37

0.903

0.126

0.262

38

77.6

22.9

0.070

 

60-69

103

6.6

4.7

 

102

2.27

3.36

 

98

0.895

0.134

 

102

81.9

16.7

 
 

70-79

86

7.3

4.7

 

87

1.75

2.38

 

84

0.888

0.139

 

85

81.1

18.1

 
 

≥80

58

5.0

4.0

 

61

1.70

2.04

 

56

0.850

0.157

 

58

73.7

20.2

 

Current AK

Yes

252

6.5

4.9

0.018

257

2.13

2.83

0.009

244

0.881

0.140

0.229

252

79.0

19.3

0.553

 

No

34

7.8

3.7

 

33

0.91

1.04

 

32

0.907

0.141

 

32

82.2

15.5

 

Severe actinic damagee

Yes

27

10.07

5.6

<0.001

27

4.59

4.07

<0.001

26

0.844

0.139

0.068

27

70.2

22.3

0.012

 

No

259

6.30

4.5

 

263

1.73

2.38

 

250

0.888

0.147

 

257

80.3

18.3

 

Suspected NMSCf

Yes

38

6.0

5.2

0.259

39

2.64

4.07

0.950

37

0.856

0.160

0.343

39

71.8

22.6

0.030

 

No

214

6.6

4.8

 

218

2.04

2.54

 

207

0.886

0.136

 

213

80.3

18.4

 

Locationsf

Face

178

6.5

4.7

0.640

182

2.11

2.68

0.531

170

0.884

0.133

0.784

179

79.4

19.0

0.671

 

Non-facial

74

6.5

5.2

 

75

2.19

3.17

 

74

0.873

0.156

 

73

78.0

20.1

 

Comorbiditiesf

Yes

175

6.7

4.9

0.357

178

2.38

3.19

0.200

170

0.860

0.151

<0.001

175

74.9

20.1

<0.001

 

No

77

6.1

4.7

 

79

1.57

1.64

 

74

0.930

0.097

 

77

88.1

13.4

 

Current AK treatment

Yes

125

7.0

5.6

0.402

127

2.43

3.38

0.186

120

0.900

0.130

0.221

123

78.2

20.3

0.609

 

No

74

5.8

3.7

 

74

1.73

2.14

 

72

0.870

0.150

 

73

81.2

16.5

 

Immunosuppressive treatmentf

Yes

25

7.2

6.0

0.869

25

4.04

4.46

0.023

23

0.876

0.143

0.900

24

70.6

25.1

0.061

 

No

227

6.4

4.7

 

232

1.93

2.52

 

221

0.881

0.140

 

226

80.1

18.3

 

Previous SCC

Yes

53

8.0

6.6

0.410

54

3.4

4.4

0.016

51

0.849

0.153

0.038

52

70.8

21.4

<0.001

 

No

233

6.4

4.2

 

236

1.7

2.0

 

225

0.892

0.136

 

213

81.3

17.9

 
  1. a26 incomplete questionnaires, b22 incomplete questionnaires, c36 incomplete questionnaires, dOne missing value, eSevere actinic damage defined as patients with multiple lesions, dominated by grade II-III AKs with moderate to severe field cancerization. fAnalysis of “Suspected NMSC”, “Locations”, “Comorbidities” and “Immunosuppressive treatment” only included patients who had current AK lesion/s at the study visit and who had answered the respective questionnaire